UNSPSC 51321605: Inositol hexanicotinate

This classification denotes an anti-lipidemic agent with the molecular formula C42H30N6O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A99MK953KZ, chemically known as 1,2,3,54,6 cyclohexanehexol hexanicotinate but more generally known as inositol hexanicotinate, which bears US NIH Compound Identifier 3720. European Medicines Agency schedules Inositol nicotinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08192MIG.

UNSPSC 51321605 Inositol hexanicotinate is a Commodity code covering a specific pharmaceutical ingredient used in advanced life support and therapeutic pharmacy applications. State and local governments procuring under this code are acquiring medications and pharmaceutical products for fire rescue services, emergency medical systems, and state health and human services programs. The scope of work includes supplying FDA-compliant injectable medications with strict expiration-date and shelf-life requirements, maintaining cold-chain logistics, and fulfilling regulatory documentation including Safety Data Sheets and accessibility conformance reporting. Issuing bodies include city fire departments, state health and human services commissions, and multistate cooperative purchasing alliances administering pharmacy benefit programs for state employees and beneficiaries.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Fire Rescue Department issued an IFB (Bid No. 26P00188) in April 2026 for advanced life support medications including epinephrine, labetalol, adenosine, and diltiazem, valued at $40,000 with a one-year contract term and SLBE set-aside eligibility; the Texas Health and Human Services Commission posted an RFI in April 2026 exploring direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager channels; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 (response due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with a two-year contract term effective July 1, 2026 and pricing weighted at 75 percent of evaluation scoring.